Pharmaceuticals have been recently classified as emerging pollutants. They enter the environment mainly because of usage in human or veterinary medicine. Wastewater treatment plants are known to be the major point source of releasing considerable amounts of pharmaceuticals into the aquatic environment. Furthermore, they continuously seep into surface water or groundwater, which could be a source of drinking water. The concentrations measured in the environment are relatively low; a few μg/L in wastewaters, where the highest concentrations are generally found, while the concentrations measured in surface or drinking waters are notably lower in the range of ng/L or pg/L. Despite these low concentrations of each individual pharmaceutical, the mixture of all present multiple substances may pose a great risk to non-target organisms or even human health. Various studies have already shown the bioaccumulation of pharmaceutical compounds and their negative effects such as morphological, cytological and behavioural malfunctions. Pharmaceutical occurrences in the environment were first published in 1970. However, in recent years, there has been an increase of similar papers, most probably owing to the improvement of analytical methods which enable the analysis of large numbers of substances in extremely low concentrations. Most often, an environmental analysis consist of a combination of appropriate sample preparation and a highly sensitive analytical method. According to the currently available scientific literature, the liquid chromatography coupled with tandem mass spectrometry in combination with a sample pre-concentration step seems to be the method of choice. In this doctoral thesis, we researched the sample preparation and the instrumental analytical methods. Furthermore, we developed a liquid chromatography method coupled with tandem mass spectrometry for the determination of pharmaceutical residues in wastewaters, surface waters, drinking waters, and in fish tissue. Regarding the extraction from wastewaters, two innovative approaches were developed. Firstly, an extraction based on solid phase extraction, namely the semi-automated SPE-DEX method. The second method was the stir-bar sorptive extraction. Both methods were validated; however, the first one was better suited for monitoring a large number of active substances (> 100). Afterwards, a comparison between the semi-automated and manual solid phase extraction confirmed the similarity of the validation parameters. Moreover, the semi-automated system has several advantages: automaticity, a high rate of sample processing, simultaneous filtration and extraction, better repeatability, and a lower probability of extraction disc clogging. Therefore, the semi-automated SPE-DEX method was chosen for the analysis of wastewaters from 19 wastewater treatment plants. A total of 46 wastewater samples were collected; 33 effluent wastewaters and 13 influent wastewaters in the period from May to August 2016. The presence of 104 pharmaceutical residues was tested using liquid chromatography coupled with tandem mass spectrometry with a single run of 8 minutes per sample. Regarding the influent samples, a total of 90 analytes out of 104 were present in at least one sample at average concentrations between 1 ng/L and 116 μg/L. In the effluent samples, we detected a total of 98 analytes out of 104 in at least one sample. The average concentrations were between 1 ng/L and 11 μg/L. In the influent wastewater samples, salicylic acid had the highest average concentration (116 μg/L) and was present in 92% of the samples. High concentrations were also measured for paracetamol (18 μg/L), metformin (17 μg/L), and caffeine (16 μg/L). Altogether, 12 analytes with a frequency of over 85% were present in concentrations above 1 μg/L, with the exception of lacosamide (7 μg/L), which was present only in one single sample. 31 analytes were detected in all samples. Regarding the highest concentrations found in effluent samples, the following analytes were present: tramadol (11 μg/L), hydrochlorothiazide (5 μg/L), metformin (4 μg/L) and salicylic acid (4 μg/L). Altogether 10 analytes with a frequency of over 60% were present in concentrations above 1 μg/L, with the exception of fluoxetine (1 μg/L), which was present in three samples and salicylic acid in one third of the samples. 14 analytes were detected in all samples. The analysis was followed by the development of an extraction method for surface waters. A manual solid phase extraction was used because it enables a higher concentration step. Based on the previous analysis, the most frequent effluent wastewater concentrations of pharmaceuticals were used as the basis for pre-selection of target compounds in surface waters. Altogether 44 analytes were included. The optimised solid phase extraction was evaluated and it showed the suitable validation parameters. Finally, six samples from different Slovene regions (five river samples and one lake sample) were analysed. 42 of all target pharmaceuticals (n = 43, one analyte was excluded due to the presence of a high background signal) were detected in at least two samples; 29 of them were detected in all samples. The concentration range of the measured pharmaceuticals was between 0.08 and 47 ng/L, the highest measured concentration was for valsartan (average 11 ng/L, median 4 ng/L). Furthermore, high concentrations were measured for tramadol, which had an average concentration of 5 ng/L (median 1.2 ng/L), and sulfamethoxazole with an average concentration of 6 ng/L (median 6.3 ng/L). The developed extraction method was adjusted for the extraction from drinking water samples. The sample volume was higher, thus increasing the concentration factor. The optimised method was evaluated and was shown to provide suitable validation parameters, especially the higher sensitivity. The method was applied to 18 drinking water samples. Among the 54 investigated substances, we confirmed the presence of 13 pharmaceuticals in at least one sample. Azithromycin was present in all samples. In general, the concentrations were very low, typically below 1 ng/L; the highest concentration was determined for azithromycin (26 ng/L) and caffeine (14 ng/L). The obtained data was used to speculate the amount of the analysed pharmaceuticals that humans take in with drinking water throughout their lifespan. We postulated the life span of 81 years and the consumption of 2 L of water daily. The sum of all monitored contaminants based on their highest measured values would be 3 mg in 81 years. Therefore it can be concluded that the risks the monitored pharmaceuticals present to human health are negligible. Regarding all three types of tested samples, it can be observed that all the pharmaceuticals present in drinking waters were also detected in surface and wastewaters. From the measured concentrations, the following conclusion can be drawn: The probability of pharmaceutical occurrence in surface and drinking water is greater when a very high concentration was measured in wastewater effluents, and/or when the individual analyte in the wastewaters was detected very frequently. In the last part of the sample preparation development, we optimized a QuEChERS (Quick, Easy, Cheap, Effective, Rugged and Safe) extraction protocol for extraction of drug residues from fish tissue. The optimised method was validated for 56 analytes. The method was used for monitoring target analytes in fish tissue. 13 samples of muscle, skin and gill tissues were analysed. The study showed the detection of 75% of all target analytes in at least one sample. Metoprolol was detected in all samples (< LOQ–0.7 ng/g). Furthermore, caffeine (< LOQ–3.2 ng/g), its metabolite 1,7-dimethylxanthine (< LOQ) and valsartan (0.1–0.4 ng/g) were detected in more than half of the samples. The highest average concentrations were measured for ciprofloxacin (19.2 ng/g), enalapril (16.2 ng/g) and haloperidol (14.0 ng/g) in the skin and gills. Interestingly, the concentrations measured in the muscles were lower or even below the limits of quantification. Regarding these data, human exposure via the ingestion of fish muscles is most probably low or negligible. The research of this doctoral thesis confirmed the presence of pharmaceuticals in wastewaters, surface waters, drinking waters, and fish tissue. Furthermore, the impact of wastewater on the continuous release of pharmaceuticals into the environment was confirmed. Therefore, we developed a treatment process that would effectively degrade pharmaceuticals in wastewaters. Firstly, the electrochemical degradation efficiency of the investigated compounds by boron-doped diamond electrode material was tested under laboratory conditions. The material in situ produced free radicals which effectively reacted with organic matter and provoked degradation. The treatment in an electrolytic cell with a boron-doped diamond electrode degraded more than 85% of the initial concentration for 7 out of 10 target compounds; however, slightly lower degradation efficiency in real wastewaters was observed. The latter fact is tightly correlated with a shorter treatment time in order to demonstrate the sewage treatment process under real conditions and with higher amount of organic material, which also react with free radicals. Furthermore, the developed electrolytic cell was afterwards used as an additional treatment step in a hospital wastewater treatment plant within European project LIFE. Some extra optimisation was needed, such as a higher number of electrolytic cells, a higher current density, and the use of extra cleaning filter. Finally, the comparison between biological and electrochemical treatment revealed a superiority of the latter approach based on 53% overall improvement in terms of pharmaceuticals degradation. The entire treatment process of the biological treatment plant with an advanced oxidation process successfully degraded more than 86% of the initial concentration of each analyte. To summarize, the doctoral thesis highlighted the presence of pharmaceutical residue in the environment. To the best of our knowledge, this was the first demonstration of a simultaneous analysis of over 100 analytes using a QqQ mass analyser. The developed methods will greatly facilitate the detection of numerous residues of pharmaceuticals in environmental samples. Our observation of wastewaters, surface waters, drinking waters, and fish tissue represents the first research with comprehensive data for the Slovene region. Based on the found concentrations in environmental waters, with the emphasis on drinking water and fish tissue, we can estimate the environmental burden and risk for humans. We can conclude that the risk for humans is minimal and that it is somewhat higher for organisms that are exposed to wastewater discharges throughout their live cycles. Finally, the research resulted in the development of a highly efficient process for the degradation of pharmaceuticals. We can say that this new technology could be a viable and feasible option for upgrading existing wastewater treatment plants in order to achieve a significantly greater cleaning efficiency, and for lessening the ecological burden. The presented data can be the basis for further introduction of routine monitoring and might represent the preposition for an extension to the Watch List from Water Framework Directive (established in Directive 2008/105/EC of the European Parliament and of the Council of Europe).
|